Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
CA 2485120 C · Owner: The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services · Inventors: Zhang, Mei-Yun; Dimitrov, Dimiter S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides an antibody to human immunodeficiency virus (HIV) envelope glycoprotein that can recognize one or more strains of HIV wherein the epitope of HIV recognized by the antibody is inducible and , wherein the antibody binding to the epitope is enhanced by the presence of CD4 and the HIV co-receptor, and related fusion proteins conjugates, nucleic , acids, vectors, host cells compositions and methods of use to inhibit an infection of a human at risk of becoming infected with HIV to reduce the , severity of an infection of a human infected with HIV and to treat an , infection of a human with HIV.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 6, 2003 and granted February 19, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 6, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 6, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.